

## Remarks

Applicants thank Examiner Kumar for the courtesy of the February 2, 2009 telephonic interview, during which the rejections of the claims under 35 U.S.C. § 112, first paragraph, and 35 U.S.C. § 103(a) were discussed. Applicants respectfully note that no agreement was made with respect to the claim amendments proposed during the interview, given that the proposed amendments were merely suggestions. Applicants further note that a Response to the outstanding Office Action containing the aforementioned rejections was filed on February 6, 2009, and any amendments made therein are without prejudice.


The foregoing amendments to the Specification have been made to correct obvious, typographical errors. In example 12 and 27, the structure and named did not correspond with physical data, this was a clerical error.

Upon entry of the above amendment, claims 1-9, 19-23, 30 and 39-42 will be pending in the instant application. Claims 1, 39, 40, 41, and 42 are independent. Applicants canceled claim 43 without prejudice to the subject matter contained therein. Accordingly, no new matter has been added.

Applicants respectfully submit that the present application is in good condition for allowance. If the Examiner believes for any reason that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at (617) 871-4125.

Respectfully submitted,

Novartis Institutes for Biomedical Research  
NIBR Patents  
220 Massachusetts Ave.  
Cambridge, MA 02139  
(617) 871-4125

  
Mark W. Milstead  
Attorney for Applicant  
Reg. No. 45,825

Date: February 23, 2008